Trials / Completed
CompletedNCT02243683
Safety Study of Immune System Modulator for Autoimmune Diseases
A Randomized, Placebo Controlled, Double Blind, Dose Escalating, Crossover, Safety and Pharmacokinetic Study of AX-024.HCl in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Artax Biopharma Inc · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the toxicity, tolerability and safety of single ascending doses of AX-024.HCl in healthy male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AX-024.HCl | |
| OTHER | Placebo |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2014-11-01
- Completion
- 2015-03-01
- First posted
- 2014-09-18
- Last updated
- 2015-10-14
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02243683. Inclusion in this directory is not an endorsement.